A carregar...
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations
Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human immunodeficiency type 1 virus (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI). DOR exhibits potent antiviral activity against wild-type virus and K103N, Y181C, and K103N/Y181C mutant viruses, with 50% in...
Na minha lista:
| Publicado no: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4808216/ https://ncbi.nlm.nih.gov/pubmed/26833152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02650-15 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|